Angiotensin Converting Enzyme 2 News and Research

RSS

APEIRON Biologics launches clinical trial of respiratory drug to treat coronavirus infection

APEIRON Biologics AG, a biotechnology company with an approved product on the market as well as a broad preclinical and clinical pipeline, today announced the launch of a Pilot investigator-initiated clinical trial with APN01, a recombinant human angiotensin-converting enzyme 2, to treat patients with severe coronavirus infection in the People's Republic of China.

26 Feb 2020

Advancing a protein drug in lettuce leaves to treat pulmonary arterial hypertension

In pulmonary arterial hypertension, high blood pressure in the lungs' arteries causes the heart to work extra hard to pump blood to the lungs and around the rest of the body.

16 Feb 2020

Cancer patients receiving common heart drugs have less heart damage from cancer therapy

Cancer patients receiving common heart drugs have less heart damage from cancer therapy, according to research presented today at EuroEcho 2019, a scientific congress of the European Society of Cardiology.

4 Dec 2019

Large gap between norms and actual quality of primary care in Canadian kidney patients

Chronic kidney disease (CKD) is a condition commonly encountered in primary health care the world over. However, a new study published in JAMA Network on September 4, 2019, shows that the standard of primary care is quite variable.

26 Oct 2019

Study compares safety and effectiveness of first-line antihypertensive drug classes

For those with extremely high blood pressure, or hypertension, there are many initial medication options -- so many that it can be hard to know which one to use.

25 Oct 2019

Father’s nutritional pattern affects child’s cardiovascular health

While couples often change their lifestyle in order to conceive faster, including crash diets, a new study in mice throws up the possibility that this kind of extreme dietary modification by the father might result in adverse effects on the child conceived in this manner.

17 Oct 2019

Heart failure medication often prescribed in lower dosages than recommended

Important medication for the treatment of heart failure are often prescribed in lower dosages than recommended by international guidelines.

1 Oct 2019

Diabetes drug can also be used to treat heart failure

Dapagliflozin, a drug that is already used to successfully treat type 2 diabetes (T2D) and prevent development of heart failure, can also be used to treat pre-existing heart failure, even in patients without T2D.

19 Sep 2019

New polypill cheaper, better at reducing cardiovascular disease

A new study from Beth Israel Deaconess Medical Center (BIDMC) has proved the cost-effectiveness and life-saving potential of the “polypill”: a single new pill which combines four commonly prescribed cardiovascular drugs into one to prevent a recurrent stroke or heart event in adult patients in low- and middle-income countries (LMIC).

5 Sep 2019

ESC guidelines highlight detrimental impact of pollution, noise on patients with chronic coronary syndromes

The detrimental impact of pollution and noise on patients with chronic coronary syndromes is highlighted for the first time in European Society of Cardiology (ESC) Guidelines published online today in European Heart Journal, and on the ESC website.

31 Aug 2019

FDA approves novel device to treat symptoms associated with advanced heart failure

The U.S. Food and Drug Administration today approved the Barostim Neo System for the improvement of symptoms in patients with advanced heart failure who are not suited for treatment with other heart failure devices, such as cardiac resynchronization therapy.

18 Aug 2019

Antihypertensive drug use linked with reduction in dementia risk

Various clinical trials indicate what effects can be expected from standardized intervention programs on the basis of existing evidence.

3 Jun 2019

Weekly pharmacy visits improve drug adherence and quality of life in elderly patients with heart failure

Elderly patients with heart failure who see a pharmacist once a week are more likely to take their tablets and be active in daily life, according to late breaking results from the PHARM-CHF randomized controlled trial presented today at Heart Failure 2019, a scientific congress of the European Society of Cardiology.

26 May 2019

Biomarkers help tailor diuretic treatment for acute heart failure patients

Adrenomedullin activity predicts which acute heart failure patients are at the greatest risk of death without diuretic treatment post-discharge, according to late breaking research presented today at Heart Failure 2019, a scientific congress of the European Society of Cardiology.

26 May 2019

New device approved by FDA for treating patients with moderate-to-severe heart failure

The U.S. Food and Drug Administration today approved the Optimizer Smart system for treating patients with chronic, moderate-to-severe heart failure who are not suited for treatment with other heart failure devices such as cardiac resynchronization therapy to restore a normal timing pattern of the heartbeat.

22 Mar 2019

New guidelines on clinical use of life-saving antibiotics

An international panel of the foremost researchers on infectious disease and antimicrobials has formed new guidelines on the use of polymyxins, a class of antibiotics employed as a last resort to treat deadly, drug-resistant bacteria.

11 Mar 2019

Study sheds new light on left ventricular dysfunction in ischemic heart disease

Ischemic heart disease is a growing cause of heart failure owing to the increasing prevalence of diabetes, hypertension, and obesity.

17 Feb 2019

Study finds underutilization of aspirin to prevent colorectal cancer in high risk patients

Colorectal cancer is the third most common cause of cancer deaths in the United States and advanced colorectal polyps are a major risk factor.

7 Feb 2019

Review highlights calcium handling mechanisms involved in reperfusion injury

Stroke and myocardial infarction (MI) are a significant cause of death and disability worldwide. However, over the past several decades because of advances in medicines (thrombolytic agents, antiplatelet drugs, beta blockers, and angiotensin converting enzyme inhibitors) and approaches to restore tissue perfusion (percutaneous coronary intervention and cardiopulmonary bypass), the mortality of MI has declined dramatically.

20 Dec 2018

Heart failure patients with stronger hearts have more depressive symptoms, lower quality of life

Heart failure patients fall into two general categories: those with weaker hearts, and those with stronger, but stiffer hearts that continue to eject the normal volume of blood with every beat.

20 Nov 2018